Literature DB >> 19273133

PML nuclear bodies as sites of epigenetic regulation.

Dora Torok1, Reagan W Ching, David P Bazett-Jones.   

Abstract

The protein-based core of a promyelocytic leukemia nuclear body (PML NB) accumulates numerous factors involved in many nuclear processes, including transcription and DNA repair. We suggest that these proteins could act on chromatin in the vicinity of the bodies. The physical dependence of PML NB structure on the integrity of the surrounding DNA implies a functional connection between the bodies and chromatin. Indeed, some genetic loci are non-randomly associated with PML NBs, indicating that nuclear bodies organize at specific loci, or are able to recruit specific genetic loci to their periphery. Since many of the factors that accumulate in PML NBs and PML-containing structures in acute promyelocytic leukemia cells are known histone methyltransferases, histone deacetylases or DNA methyltransferases, we suggest that PML NBs may have a role as epigenetic regulators. Down-regulation of normal PML protein, observed in a variety of cancers, may impair epigenetic regulation in early tumorigenesis, which ultimately leads to genetic instability and cellular transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273133     DOI: 10.2741/3311

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  31 in total

1.  N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.

Authors:  Prashant Sharma; Rodolfo Murillas; Huafeng Zhang; Michael R Kuehn
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

2.  The MORC family: new epigenetic regulators of transcription and DNA damage response.

Authors:  Da-Qiang Li; Sujit S Nair; Rakesh Kumar
Journal:  Epigenetics       Date:  2013-05-17       Impact factor: 4.528

3.  Loss of Arc attenuates the behavioral and molecular responses for sleep homeostasis in mice.

Authors:  Ayako Suzuki; Masashi Yanagisawa; Robert W Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

Review 4.  Chromatin dynamics in DNA double-strand break repair.

Authors:  Lei Shi; Philipp Oberdoerffer
Journal:  Biochim Biophys Acta       Date:  2012-01-17

5.  Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.

Authors:  Irena Draskovic; Nausica Arnoult; Villier Steiner; Silvia Bacchetti; Patrick Lomonte; Arturo Londoño-Vallejo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

6.  Impact of the adenoviral E4 Orf3 protein on the activity and posttranslational modification of p53.

Authors:  Caroline J DeHart; David H Perlman; S J Flint
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

7.  The adenoviral oncogene E1A-13S interacts with a specific isoform of the tumor suppressor PML to enhance viral transcription.

Authors:  Julia Berscheminski; Peter Groitl; Thomas Dobner; Peter Wimmer; Sabrina Schreiner
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

8.  Recombinogenic telomeres in diploid Sorex granarius (Soricidae, Eulipotyphla) fibroblast cells.

Authors:  N S Zhdanova; I Draskovic; J M Minina; T V Karamysheva; C L Novo; W-Y Liu; R M Porreca; A Gibaud; M E Zvereva; D A Skvortsov; N B Rubtsov; A Londoño-Vallejo
Journal:  Mol Cell Biol       Date:  2014-05-19       Impact factor: 4.272

9.  Influence of ND10 components on epigenetic determinants of early KSHV latency establishment.

Authors:  Thomas Günther; Sabrina Schreiner; Thomas Dobner; Uwe Tessmer; Adam Grundhoff
Journal:  PLoS Pathog       Date:  2014-07-17       Impact factor: 6.823

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.